… advanced non-small-cell lung cancer (NSCLC). The aim of the present study was to compare
their efficacies … the comparative efficacies of gefitinib or erlotinib as the third-line therapy for …

… gefitinib or erlotinib in NSCLC and compare their efficacy. The selection criteria and efficacy
… or third-line advanced NSCLC treatment, gefitinib and erlotinib were tested as the front-line …

… are effective in treating non-small cell lung cancer (NSCLC). … compared gefitinib and placebo
as second- or third-line anti-… most important predictive factor for efficacy of TK inhibitors, so …

… Randomized trials of advanced non-small cell lung cancer (NSCLC) have demonstrated
the activity of docetaxel in second-line and erlotinib in the third-line setting after failure of …

… the treatment of metastatic NSCLC. The objective of this study was to compare the efficacy
and toxicity of erlotinib, gefitinib, … or placebo in second- or third-line treatment. Median overall …

… was consistent across various subgroups, the pooled efficacies for PFS, OS, and ORR were
… A phase III RCT compared gefitinib and erlotinib in EGFR mutation-positive NSCLC and …

… III trials reporting the efficacy of gefitinib or erlotinib as maintenance therapy (single or …
to detect the difference in OS. Also, the widespread use of second and third line treatment at …

… the efficacy of egfr tyrosine kinase inhibitors (tkis) compared … therapy in patients who are
EGFR wild-type, but the selected agent should be administered as second- or third-line therapy. …

… Erlotinib has proven efficacy as second-/third-line treatment … Afatinib and gefitinib have also
demonstrated efficacy in the … In the IRC assessment, the benefit of erlotinib compared with …

… routinely used to treat non-small cell lung cancer (NSCLC) in patients with common activating
mutations of the EGFR gene. The aim of the study was to compare the efficacies of EGFR‑…